Mårten Falkenberg/ Vascular News
Aug 31, 2025, 07:12
Late-Breaking SWEDEPAD Trial Finds No Benefit of Drug-Coated Balloons and Stents, Raises Safety Concerns
Vascular News shared an important post on LinkedIn:
“BREAKING NEWS: Drug-coated balloons and stents were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in the SWEDEPAD 1 and 2 trials. In addition, higher five-year mortality with drug-coated devices in patients with intermittent claudication was noted, leading researchers to stress that the safety of paclitaxel-coated devices is an “ongoing discussion”.
These late-breaking findings were presented today at the European Society of Cardiology (ESC) 2025 congress (29 August–1 September, Madrid, Spain) and simultaneously published in The Lancet Group.”
Read more here.
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 14:46Mital Jhaveri: Anticoagulant Approval and Uptake Timeline
-
Apr 23, 2026, 14:42Salih Ehsan: Bradykinin-Mediated Transfusion Reactions in Patients on ACE Inhibitors
-
Apr 23, 2026, 14:39Mona Alfaraj: Don’t Miss the Chance to Be Part of the 2nd International Hematology and Hemostasis Conference
-
Apr 23, 2026, 14:11Emerging Contributions to Hemostasis from Recipients of the Christine Lee Young Researcher Awards – WFH
-
Apr 23, 2026, 13:52Joffrey Feriel: A Revised ISTH Definition of Disseminated Intravascular Coagulation
-
Apr 23, 2026, 13:39Mazou Ngou Temgoua: Cancer and VTE – Toward Truly Personalized Anticoagulation
-
Apr 23, 2026, 13:35Jecko Thachil: Risk Assessment and Clinical Management of Nephrotic Syndrome–Associated Thrombosis
-
Apr 23, 2026, 12:18Mona Ranade: A Contemporary Framework for Managing Right Heart Thrombus in PE
-
Apr 23, 2026, 11:59Strengthening Hemophilia Care Through Collaboration and Commitment in India at IHC X 2026 – Hemophilia Federation India